Table 3:
Relative Odds of Initiation of Adjuvant Therapy: Univariable and Multivariable Logistic Regression Models, Odds Ratios (95% CI)
| Univariable | P value | Overall P value | Multivariable | P value | Overall P value | |
|---|---|---|---|---|---|---|
| SED (reference: Low SED) | 0.506 | 0.286 | ||||
| Moderate SED | 0.71 (0.36, 1.40) | 0.324 | 0.55 (0.22, 1.32) | 0.184 | ||
| High SED | 1.06 (0.48, 2.44) | 0.898 | 1.12 (0.39, 3.31) | 0.837 | ||
| Age | 0.92 (0.89, 0.96) | <0.001 | 0.88 (0.83, 0.94) | <0.001 | ||
| Male sex (reference: female) | 0.58 (0.30, 1.09) | 0.096 | 0.35 (0.15, 0.77) | 0.011 | ||
| Race (reference: White) | 0.403 | 0.416 | ||||
| Black | 2.89 (0.55, 53.16) | 0.314 | 1.34 (0.18, 27.69) | 0.803 | ||
| Other / unknown | 2.64 (0.50, 48.89) | 0.357 | 5.39 (0.61, 136.18) | 0.194 | ||
| Insurance (reference: private) | 0.031 | 0.167 | ||||
| Government with private supplement | 0.48 (0.19, 1.10) | 0.094 | 0.97 (0.30, 2.98) | 0.962 | ||
| Government | 0.31 (0.12, 0.72) | 0.009 | 0.46 (0.13, 1.44) | 0.193 | ||
| Distance from Moffitt (miles) | 1.00 (0.99, 1.00) | 0.502 | 1.00 (0.99, 1.01) | 0.715 | ||
| Charlson comorbidity index | 0.77 (0.63, 0.95) | 0.015 | 1.36 (0.94, 2.01) | 0.113 | ||
| Diabetes mellitus (reference: no) | 0.61 (0.33, 1.17) | 0.127 | 0.66 (0.28, 1.54) | 0.330 | ||
| BMI | 0.99 (0.94, 1.05) | 0.720 | 0.98 (0.92, 1.05) | 0.559 | ||
| Preoperative biliary stent (reference: none) | 1.00 (0.54, 1.82) | 0.988 | 1.21 (0.47, 3.00) | 0.681 | ||
| Neoadjuvant Therapy (reference: none) | 1.02 (0.55, 1.95) | 0.951 | 0.91 (0.34, 2.47) | 0.843 | ||
| ASA class 3 (reference: ASA 2) | 0.34 (0.16, 0.67) | 0.003 | 0.58 (0.22, 1.45) | 0.252 | ||
| Distal pancreatectomy +/− splenectomy (reference: Whipple/total pancreatectomy) | 1.32 (0.63, 3.05) | 0.488 | 1.27 (0.34, 4.86) | 0.728 | ||
| Venous reconstruction (reference: none) | 0.92 (0.40, 2.41) | 0.859 | 1.68 (0.50, 6.45) | 0.423 | ||
| Estimated blood loss | 1.00 (1.00, 1.00) | 0.021 | 1.00 (0.99, 1.00) | 0.060 | ||
| Operative time | 0.90 (0.80, 1.02) | 0.100 | 0.87 (0.72, 1.04) | 0.131 | ||
| Pathologic tumor stage (reference: CR/in situ) | 0.602 | 0.691 | ||||
| T1 | 2.80 (0.48, 22.14) | 0.268 | 2.02 (0.21, 28.58) | 0.565 | ||
| T2 | 1.23 (0.33, 3.76) | 0.729 | 1.06 (0.22, 4.54) | 0.939 | ||
| T3 | 1.02 (0.27, 3.14) | 0.977 | 0.68 (0.13, 3.08) | 0.622 | ||
| Pathologic nodal stage (reference: N0) | 0.262 | 0.157 | ||||
| N1 | 1.78 (0.90, 3.63) | 0.102 | 2.71 (0.99, 7.70) | 0.055 | ||
| N2 | 1.19 (0.54, 2.79) | 0.669 | 1.78 (0.53, 6.30) | 0.361 | ||
| R1 Margin status (reference: R0) | 1.09 (0.43, 3.37) | 0.868 | 0.39 (0.11, 1.53) | 0.159 | ||
| Lymphovascular invasion (reference: none) | 1.15 (0.59, 2.16) | 0.682 | 0.85 (0.27, 2.62) | 0.784 | ||
| Perineural invasion (reference: none) | 1.00 (0.43, 2.14) | 0.997 | 0.99 (0.30, 3.14) | 0.986 | ||
| Clavien grade 3/4 complication (reference: none) | 0.31 (0.15, 0.66) | 0.002 | 0.22 (0.08, 0.57) | 0.002 |